Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients
Portfolio Pulse from Vandana Singh
IMUNON Inc (NASDAQ:IMNN) reported positive topline results from its Phase 2 OVATION 2 Study for its lead candidate IMNN-001 in advanced ovarian cancer patients. The study showed significant improvements in overall survival and progression-free survival compared to standard-of-care treatments. The company plans to discuss a Phase 3 study protocol with the FDA soon. IMNN stock surged 158% following the news.
July 30, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON Inc's (NASDAQ:IMNN) lead candidate IMNN-001 showed significant improvements in overall survival and progression-free survival in a Phase 2 study for advanced ovarian cancer. The company plans to discuss a Phase 3 study with the FDA. IMNN stock surged 158% following the news.
The positive Phase 2 results for IMNN-001 indicate a significant advancement in treatment for advanced ovarian cancer, which is likely to boost investor confidence and drive the stock price up. The planned Phase 3 study further adds to the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100